about
Outcomes of Liver Transplantation During Adulthood After Kasai Portoenterostomy Due to Biliary AtresiaEfficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.Coping Strategies in Liver Transplant Recipients and Caregivers According to Patient Posttraumatic Growth.Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical MicrManagement of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) anAntitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma.The utility of the macro-aggregated albumin lung perfusion scan in the diagnosis and prognosis of hepatopulmonary syndrome in cirrhotic patients candidates for liver transplantation.Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study.Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence.Post-transplant lymphoproliferative disease in liver transplant recipients.Recurrent Hepatocellular Carcinoma After Liver Transplantation: Analysis of Risk Factors.Survival Outcomes in Liver Transplantation With Elderly Donors: Analysis of Andalusian Transplant Register.Analysis of the First 1000 Liver Transplants in Virgen del Rocío Hospital.Point-of-care haemostasis monitoring during liver transplantation reduces transfusion requirements and improves patient outcome.Implication of the presence of a variant hepatic artery during the Whipple procedure.Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.Modigraf administration through jejunostomy in liver transplant recipient: case report.T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection.Post-traumatic growth and its relationship to quality of life up to 9 years after liver transplantation: a cross-sectional study in Spain.Cancers of new appearance in liver transplant recipients: incidence and evolution.Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients.Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation.Influence of donor age on survival in liver transplantation due to hepatitis C virus.Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation.Development and validation of a specific questionnaire for evaluating the impact of gastrointestinal symptoms on the health-related quality of life of transplant patients.Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.Efficacy and safety of mycophenolate mofetil as part of induction therapy in liver transplantation.Comparison of the affective symptomatology between liver transplant recipients and patients with multiple sclerosis considering their functional impairment.Evolution of anxious-depressive symptomatology in liver and kidney transplant recipients: hospitalization and 12-month post-transplantation phases.Longitudinal study of liver transplant recipients' quality of life as a function of their perception of general health: at waiting list and at 3, 6, and 12 months post-transplantation.Influence of acute cellular rejection and depressive symptomatology on liver transplant recipients' quality of life.Fifteen years of follow-up of a liver transplant recipient with glycogen storage disease type Ia (Von Gierke disease).Alternative outflow reconstruction in domino liver transplantation.De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood.Impact of the learning curve on the outcome of domino liver transplantation.
P50
Q29396194-5E465841-319B-4E55-82B7-D0F6873B159AQ33386028-840D13C4-4042-48D8-A2C0-52BA716DB8ACQ36102839-2FE0AE46-1799-406F-B9A7-C827B40430D4Q36325357-D799AA6A-77B9-4CF1-BC1E-69B2063314ABQ37594977-B9E21FA1-D642-43AB-AA0C-E9F2F8AD58A3Q38092937-9147A243-27BD-4BDE-9749-0B7CB116AB69Q38092938-C5D95898-2209-455E-A84E-B7FF99408130Q38850012-47551359-BC4D-46FF-9E82-4505BA40F274Q38902966-10A35867-382C-42B6-A9EE-DFC36247DA65Q39179560-89279189-EDDB-4505-8DA7-C7B5DF33EC93Q39278937-2C98EC90-9869-492E-8D9E-BE9F7D1BF47EQ39309308-B6E06D81-AA98-47C9-B665-79702B3259F8Q40434294-D3B085AC-C136-4705-A4AA-AEA805605F1DQ40434299-87394843-E03E-4774-B34F-25A887D10BDFQ40434305-7AF35561-E046-4A0D-8F99-8AD7819D178DQ41008890-E4139EAA-ABEA-488A-A91F-5122A4682EADQ41615018-E53993BE-6358-4387-A400-5FCF122F3142Q42105382-459A8531-99E8-46F3-9B10-A399EAE70841Q42250525-ED1EDC83-65F1-4B61-8579-EE4A7B0E086FQ42366721-9B1B9ACE-463A-4DFC-8D8D-7DDF36CB07DFQ42376868-134DB1F2-42B5-434C-B930-4B0FDC320310Q42503988-92516F4E-979B-44C5-9122-3D2A94CCDF70Q43123074-C1C425AB-9E09-4A68-97CA-AC62406532B2Q43284019-D8B48DA9-F859-4B6D-93CC-C36D548CE90FQ43511328-A96C77E0-49A4-4F67-A9F7-983B80234C9DQ45388680-22E991B5-7C18-4F88-B59E-EC55401F0F6EQ45388683-CAFFA8D7-8281-475D-BCB5-F6540D887BAEQ46199817-E226CAF2-699D-465D-A31E-6282392D710BQ46246074-06AAFF0B-3D56-4013-AA1D-CAAEE8DCCCE9Q46246088-30CEA421-6581-4508-8B55-C3C05187A13CQ46873964-21E892E5-8BC3-4A69-91D8-A4BEFA635944Q47750516-F8741925-2A8E-4AD0-89F7-F58156D822A7Q47947112-5379DDD5-ADAC-46D0-896D-300EEAD72AB5Q47947120-D3FE2D35-7456-4331-8A02-B44049EA6A81Q48050920-ED319DBC-DD90-492F-9A80-DB27986180DCQ48121275-E396D504-1A35-4069-887F-552B83E4D884Q48137653-8B5EA3AD-0D15-4501-B1D5-F6769F571942Q50283514-865D3EAE-4BCF-4820-80CE-0059851D9B5EQ50557198-FCB5C9B5-535A-4990-969D-7E8440DCE56BQ50622211-3773B06E-E51E-4AF4-8192-45D8397F5A8E
P50
description
researcher
@en
wetenschapper
@nl
name
Gómez Bravo M
@ast
Gómez Bravo M
@nl
Miguel Angel Gómez Bravo
@en
type
label
Gómez Bravo M
@ast
Gómez Bravo M
@nl
Miguel Angel Gómez Bravo
@en
altLabel
Gómez Bravo M
@en
prefLabel
Gómez Bravo M
@ast
Gómez Bravo M
@nl
Miguel Angel Gómez Bravo
@en
P106
P31
P496
0000-0002-5155-3508